Inclusion of TSPY-EGFP construct in Group-2 mice showed a significant reduction of tumor size while those injected with TSPY-EGFP alone (Group-3) or control (Group-4) showed no tumor in the respective livers (Fig. 1A & B), suggesting that TSPY alone is incapable of inducing tumor development while TSPY co-expression with the oncogenes led to a repression/reduction of tumorigenic growth in this mouse HCC model. The gene discussed is TSPY1; the disease is hepatocellular carcinoma.